These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 20385899)

  • 1. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.
    Chamberlain MC; Lassman AB; Iwamoto FM
    Neurology; 2010 Apr; 74(15):1239-41. PubMed ID: 20385899
    [No Abstract]   [Full Text] [Related]  

  • 2. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Chamberlain MC
    Neurology; 2009 Feb; 72(8):772-3; author reply 773-4. PubMed ID: 19237713
    [No Abstract]   [Full Text] [Related]  

  • 3. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Mrugala MM
    Neurology; 2009 Feb; 72(8):773; author reply 773-4. PubMed ID: 19248218
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
    Cohen MH; Shen YL; Keegan P; Pazdur R
    Oncologist; 2009 Nov; 14(11):1131-8. PubMed ID: 19897538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab and recurrent malignant gliomas: a European perspective.
    Wick W; Weller M; van den Bent M; Stupp R
    J Clin Oncol; 2010 Apr; 28(12):e188-9; author reply e190-2. PubMed ID: 20159801
    [No Abstract]   [Full Text] [Related]  

  • 6. Mechanisms of evasion to antiangiogenic therapy in glioblastoma.
    Rose SD; Aghi MK
    Clin Neurosurg; 2010; 57():123-8. PubMed ID: 21280504
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of avastin in the management of recurrent glioblastoma.
    Sweet JA; Feinberg ML; Sherman JH
    Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optic neuropathy in patients with glioblastoma receiving bevacizumab.
    Chamberlain MC; Raizer J; Schiff D; Sherman JH
    Neurology; 2010 Jul; 75(3):289-90; author reply 290. PubMed ID: 20644159
    [No Abstract]   [Full Text] [Related]  

  • 9. Bevacizumab for recurrent hemangioendothelioma.
    Trautmann K; Bethke A; Ehninger G; Folprecht G
    Acta Oncol; 2011 Jan; 50(1):153-4. PubMed ID: 20950228
    [No Abstract]   [Full Text] [Related]  

  • 10. Enigma of a rapid introduction of antiangiogenic therapy with bevacizumab in glioblastoma: a new era in the treatment of malignant brain tumours?
    Henriksson R; Bergström P; Johansson M; Sandström M
    Acta Oncol; 2009; 48(1):6-8. PubMed ID: 18932097
    [No Abstract]   [Full Text] [Related]  

  • 11. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme.
    Spasic M; Chow F; Tu C; Nagasawa DT; Yang I
    Neurosurg Clin N Am; 2012 Jul; 23(3):417-27. PubMed ID: 22748654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab for renal cell carcinoma, glioblastoma, and other solid tumors.
    Wilkes GM
    Oncology (Williston Park); 2009 Oct; 23(11 Suppl Nurse Ed):54-6. PubMed ID: 19856612
    [No Abstract]   [Full Text] [Related]  

  • 14. Bevacizumab for glioblastoma: what can we learn from patterns of progression?
    Wen PY; Junck L
    Neurology; 2014 May; 82(19):1670-1. PubMed ID: 24727316
    [No Abstract]   [Full Text] [Related]  

  • 15. Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma.
    Shapiro LQ; Beal K; Goenka A; Karimi S; Iwamoto FM; Yamada Y; Zhang Z; Lassman AB; Abrey LE; Gutin PH
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):636-42. PubMed ID: 22765876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma.
    Numnum TM; Rocconi RP; Whitworth J; Barnes MN
    Gynecol Oncol; 2006 Sep; 102(3):425-8. PubMed ID: 16797681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of rapidly progressive moyamoya syndrome with bevacizumab treatment for glioblastoma in a child with neurofibromatosis type 1.
    Ullrich NJ; Zimmerman M; Smith E; Irons M; Marcus K; Kieran MW
    J Child Neurol; 2011 Feb; 26(2):228-30. PubMed ID: 20823033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photodynamic therapy may worsen the prognosis of highly myopic choroidal neovascularisation treated by intravitreal bevacizumab.
    Ruiz-Moreno JM; Montero JA; Gomez-Ulla F
    Br J Ophthalmol; 2009 Dec; 93(12):1693-4. PubMed ID: 19939802
    [No Abstract]   [Full Text] [Related]  

  • 19. Radiotherapy and bevacizumab for intramedullary and leptomenigeal metastatic glioblastoma: a case report and review of the literature.
    Fiorentino A; Caivano R; Chiumento C; Cozzolino M; Fusco V
    Int J Neurosci; 2012 Nov; 122(11):691-4. PubMed ID: 22720749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme.
    Francesconi AB; Dupre S; Matos M; Martin D; Hughes BG; Wyld DK; Lickliter JD
    J Clin Neurosci; 2010 Aug; 17(8):970-4. PubMed ID: 20541421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.